Please Wait.....
Report
Age Related Macular Degeneration Market By Drug Type (Aflibercept, Ranibizumab, Others) , By Disease Type (Wet Age Related Macular Degeneration (AMD) , Dry Age Related Macular Degeneration (AMD)) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Market Report I 2024-07-01 I 216 Pages I Allied Market Research
Age Related Macular Degeneration Market
The age related macular degeneration market was valued at $10.0 billion in 2023 and is projected to reach $16.2 billion by 2033, growing at a CAGR of 5% from 2024 to 2033.
Age related macular degeneration is a visual impairment in which the central portion of the retina, known as macula,deteriorates. Beginning with slight blurred vision, the disease eventually leads to loss of central eyesight. There are two categories of the disease: dry (atrophic) and wet (neovascular). Gradual thinning of the macula occurs in dry macular degeneration, whereas wet macular degeneration happens due to abnormal growth of blood vessels under the retina.
Exponential increase in the aging population and rise in prevalence of the disease are the key drivers of the age related macular degeneration market. In addition, advancements in diagnostic techniques are leading to early detection and timely treatment of the disease, thereby augmenting the market development. In recent times, AI and deep learning are revolutionizing the landscape of age related macular degeneration diagnosis and treatment. The technology helps in precise detection of the eye condition and assesses the risk pertaining to the progression of the disease to advanced stages.
However, in case of disease advancement to high stages, treatment procedures exhibit limited to no efficacy, thereby restraining the growth of the age related macular degeneration market. Moreover, the high expense of purchasing medications essential for curing the disease, such as anti-vascular endothelial growth factor injections, constraints several patients from undergoing the treatment. This hampers the development of the market. According to an article published by the UK-based scientific journals publisher-BioMed Central- age related macular degeneration is one of the leading causes of vision loss and by 2040, the disease is anticipated to impact 288 million individuals.
Segment Review
The age related macular degeneration market is segmented into drug type, disease type, distribution channel, and region. On the basis of drug type, the market is divided into aflibercept, ranibizumab, and others. Depending on disease type, it is bifurcated into wet age related macular degeneration (AMD) and dry age related macular degeneration (AMD). As per distribution channel, it is classified into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of drug type, theafliberceptsegment dominates the age related macular degeneration market.
Depending on disease type, the wet age-related macular degeneration (AMD) segment acquires a significant share of the market.
As per distribution channel, the hospital pharmacy segment leads in the market.
Region wise, the market exhibits robust growth inNorth America.
Competition Analysis
The leading players operating in theglobal age related macular degeneration market include Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Biogen, Bayer AG, Coherus Biosciences Inc, Sanofi, Apellis Pharmaceuticals, Bausch Health Companies Inc., and Ionis Pharmaceuticals, Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Expanded list for Company Profiles
- Historic market data
Key Market Segments
By Drug Type
- Aflibercept
- Ranibizumab
- Others
By Disease Type
- Wet Age Related Macular Degeneration (AMD)
- Dry Age Related Macular Degeneration (AMD)
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
- Key Market Players
- Regeneron Pharmaceuticals Inc.
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Biogen
- Bayer AG
- Coherus Biosciences Inc
- Sanofi
- Apellis Pharmaceuticals
- Bausch Health Companies Inc.
- Ionis Pharmaceuticals, Inc
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: TANK LINER MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. PVC Liner
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. PE Liner
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
CHAPTER 5: TANK LINER MARKET, BY APPLICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Application
5.2. Water Tanks
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Oil Tanks
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: TANK LINER MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Type
6.2.3. Market Size and Forecast, By Application
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Tank Liner Market
6.2.5.1. Market Size and Forecast, By Type
6.2.5.2. Market Size and Forecast, By Application
6.2.6. Canada Tank Liner Market
6.2.6.1. Market Size and Forecast, By Type
6.2.6.2. Market Size and Forecast, By Application
6.2.7. Mexico Tank Liner Market
6.2.7.1. Market Size and Forecast, By Type
6.2.7.2. Market Size and Forecast, By Application
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Type
6.3.3. Market Size and Forecast, By Application
6.3.4. Market Size and Forecast, By Country
6.3.5. France Tank Liner Market
6.3.5.1. Market Size and Forecast, By Type
6.3.5.2. Market Size and Forecast, By Application
6.3.6. Germany Tank Liner Market
6.3.6.1. Market Size and Forecast, By Type
6.3.6.2. Market Size and Forecast, By Application
6.3.7. Italy Tank Liner Market
6.3.7.1. Market Size and Forecast, By Type
6.3.7.2. Market Size and Forecast, By Application
6.3.8. UK Tank Liner Market
6.3.8.1. Market Size and Forecast, By Type
6.3.8.2. Market Size and Forecast, By Application
6.3.9. Rest of Europe Tank Liner Market
6.3.9.1. Market Size and Forecast, By Type
6.3.9.2. Market Size and Forecast, By Application
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Type
6.4.3. Market Size and Forecast, By Application
6.4.4. Market Size and Forecast, By Country
6.4.5. China Tank Liner Market
6.4.5.1. Market Size and Forecast, By Type
6.4.5.2. Market Size and Forecast, By Application
6.4.6. Japan Tank Liner Market
6.4.6.1. Market Size and Forecast, By Type
6.4.6.2. Market Size and Forecast, By Application
6.4.7. India Tank Liner Market
6.4.7.1. Market Size and Forecast, By Type
6.4.7.2. Market Size and Forecast, By Application
6.4.8. South Korea Tank Liner Market
6.4.8.1. Market Size and Forecast, By Type
6.4.8.2. Market Size and Forecast, By Application
6.4.9. Rest of Asia-Pacific Tank Liner Market
6.4.9.1. Market Size and Forecast, By Type
6.4.9.2. Market Size and Forecast, By Application
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Type
6.5.3. Market Size and Forecast, By Application
6.5.4. Market Size and Forecast, By Country
6.5.5. Latin America Tank Liner Market
6.5.5.1. Market Size and Forecast, By Type
6.5.5.2. Market Size and Forecast, By Application
6.5.6. Middle East Tank Liner Market
6.5.6.1. Market Size and Forecast, By Type
6.5.6.2. Market Size and Forecast, By Application
6.5.7. Africa Tank Liner Market
6.5.7.1. Market Size and Forecast, By Type
6.5.7.2. Market Size and Forecast, By Application
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Fab-Seal Industrial Liners
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Flexi-Liner
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Fabtech
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Layfield Group
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Rostfrei Steels
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Witt Lining Systems
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Walco
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Freedom Manufacturing
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Fleximake
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Wolftank Adisa
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
TABLE 1. GLOBAL AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 2. AGE RELATED MACULAR DEGENERATION MARKET FOR AFLIBERCEPT, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. AGE RELATED MACULAR DEGENERATION MARKET FOR RANIBIZUMAB, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. AGE RELATED MACULAR DEGENERATION MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 5. GLOBAL AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 6. AGE RELATED MACULAR DEGENERATION MARKET FOR WET AGE RELATED MACULAR DEGENERATION (AMD), BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. AGE RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION (AMD), BY REGION, 2024 - 2033 ($BILLION)
TABLE 8. GLOBAL AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 9. AGE RELATED MACULAR DEGENERATION MARKET FOR HOSPITAL PHARMACY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 10. AGE RELATED MACULAR DEGENERATION MARKET FOR RETAIL PHARMACY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 11. AGE RELATED MACULAR DEGENERATION MARKET FOR ONLINE PHARMACY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 12. AGE RELATED MACULAR DEGENERATION MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 13. NORTH AMERICA AGE RELATED MACULAR DEGENERATION MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 14. NORTH AMERICA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 15. NORTH AMERICA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 16. NORTH AMERICA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 17. U.S. AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 18. U.S. AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 19. U.S. AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 20. CANADA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 21. CANADA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 22. CANADA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 23. MEXICO AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 24. MEXICO AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 25. MEXICO AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 26. EUROPE AGE RELATED MACULAR DEGENERATION MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 27. EUROPE AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 28. EUROPE AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 29. EUROPE AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 30. FRANCE AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 31. FRANCE AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 32. FRANCE AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 33. GERMANY AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 34. GERMANY AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 35. GERMANY AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 36. ITALY AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 37. ITALY AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 38. ITALY AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 39. SPAIN AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 40. SPAIN AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 41. SPAIN AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 42. UK AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 43. UK AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 44. UK AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 45. REST OF EUROPE AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 46. REST OF EUROPE AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 47. REST OF EUROPE AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 48. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 49. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 50. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 51. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 52. CHINA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 53. CHINA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 54. CHINA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 55. JAPAN AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 56. JAPAN AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 57. JAPAN AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 58. INDIA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 59. INDIA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 60. INDIA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 61. SOUTH KOREA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 62. SOUTH KOREA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 63. SOUTH KOREA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 64. AUSTRALIA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 65. AUSTRALIA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 66. AUSTRALIA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 67. REST OF ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 68. REST OF ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 69. REST OF ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 70. LAMEA AGE RELATED MACULAR DEGENERATION MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 71. LAMEA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 72. LAMEA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 73. LAMEA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 74. BRAZIL AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 75. BRAZIL AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 76. BRAZIL AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 77. SOUTH AFRICA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 78. SOUTH AFRICA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 79. SOUTH AFRICA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 80. SAUDI ARABIA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 81. SAUDI ARABIA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 82. SAUDI ARABIA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 83. REST OF LAMEA AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 84. REST OF LAMEA AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE, 2024 - 2033 ($BILLION)
TABLE 85. REST OF LAMEA AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 86. REGENERON PHARMACEUTICALS INC.: KEY EXECUTIVES
TABLE 87. REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 88. REGENERON PHARMACEUTICALS INC.: OPERATING SEGMENTS
TABLE 89. REGENERON PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 90. REGENERON PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 91. NOVARTIS AG: KEY EXECUTIVES
TABLE 92. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 93. NOVARTIS AG: OPERATING SEGMENTS
TABLE 94. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 95. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 96. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 97. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 98. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
TABLE 99. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 100. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 101. BIOGEN: KEY EXECUTIVES
TABLE 102. BIOGEN: COMPANY SNAPSHOT
TABLE 103. BIOGEN: OPERATING SEGMENTS
TABLE 104. BIOGEN: PRODUCT PORTFOLIO
TABLE 105. BIOGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 106. BAYER AG: KEY EXECUTIVES
TABLE 107. BAYER AG: COMPANY SNAPSHOT
TABLE 108. BAYER AG: OPERATING SEGMENTS
TABLE 109. BAYER AG: PRODUCT PORTFOLIO
TABLE 110. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 111. COHERUS BIOSCIENCES INC: KEY EXECUTIVES
TABLE 112. COHERUS BIOSCIENCES INC: COMPANY SNAPSHOT
TABLE 113. COHERUS BIOSCIENCES INC: OPERATING SEGMENTS
TABLE 114. COHERUS BIOSCIENCES INC: PRODUCT PORTFOLIO
TABLE 115. COHERUS BIOSCIENCES INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 116. SANOFI: KEY EXECUTIVES
TABLE 117. SANOFI: COMPANY SNAPSHOT
TABLE 118. SANOFI: OPERATING SEGMENTS
TABLE 119. SANOFI: PRODUCT PORTFOLIO
TABLE 120. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 121. APELLIS PHARMACEUTICALS: KEY EXECUTIVES
TABLE 122. APELLIS PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 123. APELLIS PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 124. APELLIS PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 125. APELLIS PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 126. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES
TABLE 127. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
TABLE 128. BAUSCH HEALTH COMPANIES INC.: OPERATING SEGMENTS
TABLE 129. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
TABLE 130. BAUSCH HEALTH COMPANIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 131. IONIS PHARMACEUTICALS, INC: KEY EXECUTIVES
TABLE 132. IONIS PHARMACEUTICALS, INC: COMPANY SNAPSHOT
TABLE 133. IONIS PHARMACEUTICALS, INC: OPERATING SEGMENTS
TABLE 134. IONIS PHARMACEUTICALS, INC: PRODUCT PORTFOLIO
TABLE 135. IONIS PHARMACEUTICALS, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
FIGURE 1. GLOBAL AGE RELATED MACULAR DEGENERATION MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF AGE RELATED MACULAR DEGENERATION MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN AGE RELATED MACULAR DEGENERATION MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALAGE RELATED MACULAR DEGENERATION MARKET
FIGURE 10. GLOBAL AGE RELATED MACULAR DEGENERATION MARKET SEGMENTATION, BY DRUG TYPE
FIGURE 11. AGE RELATED MACULAR DEGENERATION MARKET FOR AFLIBERCEPT, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 12. AGE RELATED MACULAR DEGENERATION MARKET FOR RANIBIZUMAB, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. AGE RELATED MACULAR DEGENERATION MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. GLOBAL AGE RELATED MACULAR DEGENERATION MARKET SEGMENTATION, BY DISEASE TYPE
FIGURE 15. AGE RELATED MACULAR DEGENERATION MARKET FOR WET AGE RELATED MACULAR DEGENERATION (AMD), BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. AGE RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION (AMD), BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. GLOBAL AGE RELATED MACULAR DEGENERATION MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL
FIGURE 18. AGE RELATED MACULAR DEGENERATION MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 19. AGE RELATED MACULAR DEGENERATION MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 20. AGE RELATED MACULAR DEGENERATION MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 25. COMPETITIVE DASHBOARD
FIGURE 26. COMPETITIVE HEATMAP: AGE RELATED MACULAR DEGENERATION MARKET
FIGURE 27. TOP PLAYER POSITIONING, 2023
FIGURE 28. REGENERON PHARMACEUTICALS INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 29. REGENERON PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 30. REGENERON PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 31. NOVARTIS AG: NET SALES, 2021-2023 ($BILLION)
FIGURE 32. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 33. NOVARTIS AG: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 34. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2021-2023 ($BILLION)
FIGURE 35. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 36. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 37. BIOGEN: NET SALES, 2021-2023 ($BILLION)
FIGURE 38. BIOGEN: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 39. BIOGEN: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 40. BAYER AG: NET SALES, 2021-2023 ($BILLION)
FIGURE 41. BAYER AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 42. BAYER AG: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 43. COHERUS BIOSCIENCES INC: NET SALES, 2021-2023 ($BILLION)
FIGURE 44. COHERUS BIOSCIENCES INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 45. COHERUS BIOSCIENCES INC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 46. SANOFI: NET SALES, 2021-2023 ($BILLION)
FIGURE 47. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 48. SANOFI: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 49. APELLIS PHARMACEUTICALS: NET SALES, 2021-2023 ($BILLION)
FIGURE 50. APELLIS PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 51. APELLIS PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 52. BAUSCH HEALTH COMPANIES INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 53. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 54. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 55. IONIS PHARMACEUTICALS, INC: NET SALES, 2021-2023 ($BILLION)
FIGURE 56. IONIS PHARMACEUTICALS, INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 57. IONIS PHARMACEUTICALS, INC: REVENUE SHARE, BY REGION, 2023 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security